European Commission Grants Marketing Authorization to Hulio, a Humira Biosimilar, for IBD, Others

European Commission Grants Marketing Authorization to Hulio, a Humira Biosimilar, for IBD, Others
The European commission (EC) has granted marketing authorization to Mylan and Fujifilm Kyowa Kirin Biologics for Hulio, a biosimilar to AbbVie’s Humira (adalimumab). The marketing authorization covers all indications for which Humira is approved, including inflammatory bowel disease (IBD). The authorization comes on the heels of a positive opinion adopted by the Committee for Medicinal Products

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *